2017 Buyer’s Guide

This buyer’s guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

Five-Year Results Published From the COMPARE II Trial of Terumo's Nobori Biodegradable DES

 

June 26, 2017—The final 5-year report from the COMPARE II trial of an abluminal biodegradable polymer biolimus-A9–eluting stent (BP-BES) versus a durable polymer everolimus-eluting stent (DP-EES) was published by Georgios J. Vlachojannis, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

The COMPARE II trial was a prospective, randomized, multicenter, all-comers trial composed of 2,707 patients undergoing percutaneous coronary intervention (PCI) who were randomly allocated (2:1) to BP-BES (Nobori, Terumo Interventional Systems), or DP-EES (Xience, Xience-V, Xience-Prime [Abbott Vascular], or Promus [Boston Scientific]). The prespecified endpoint at 5 years was major adverse cardiac events, a composite of cardiac death, nonfatal myocardial infarction, or target vessel revascularization.

As summarized in JACC: Cardiovascular Interventions, 5-year follow-up was available in 2,657 patients (98%). At 5 years, major adverse cardiac events occurred in 310 patients (17.3%) in the BP-BES group and 142 patients (15.6%) in the DP-EES group (P = .26). The rate of the combined safety endpoint of all-cause death or myocardial infarction was 15% in the BP-BES group versus 14.8% in the DP-EES group (P = .9), whereas the efficacy measure of target vessel revascularization was 10.6% versus 9% (P = .18), respectively. The investigators noted that definite stent thrombosis rates did not differ between groups (1.5% for BP-BES vs 0.9% for DP-EES; P = 0.17).

The 5-year analysis comparing biodegradable polymer-coated BES and the durable polymer-coated EES confirms the initial early- and midterm results regarding similar safety and efficacy outcomes in this all-comers PCI population, concluded the investigators in JACC: Cardiovascular Interventions.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.